Sponsor or institution
Clinical trials and research at GI Innovation, Inc.
As of November 12, 2026, Find a Trial lists 5 clinical trials run by GI Innovation, Inc. that are recruiting, at sites in 3 countries (most in South Korea (4), United States (3), Australia (1)). 1 was first registered in the last 30 days. By phase: Phase 1/2 (4), Phase 2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 1New in 30 days
- 3Countries
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| GI-102 with Pasritamig for metastatic prostate cancer | Phase 1/2 | New York, New York and 5 other locations | Recruiting | Oct 13, 2026 |
| GI-102 plus GIB-7 to target immune aging and gut‑brain‑muscle health | Phase 2 | Charlestown, New South Wales and 1 other locations | Recruiting | Jan 23, 2026 |
| GI-108 monotherapy for people with advanced or metastatic solid tumors | Phase 1/2 | Seoul and 2 other locations | Recruiting | Sep 15, 2025 |
| Evaluating GI-102 for advanced solid tumors with or without other cancer drugs | Phase 1/2 | Scottsdale, Arizona and 10 other locations | Recruiting | Apr 24, 2023 |
| Evaluating GI-101 with Pembrolizumab, Lenvatinib, or Radiotherapy in Advanced Solid Tumors | Phase 1/2 | New York, New York and 12 other locations | Recruiting | Jul 27, 2021 |
All recruiting trials (5)
-
GI-102 with Pasritamig for metastatic prostate cancer
This trial tests GI-102 together with Pasritamig to see if it is safe and may help men whose metastatic castration-resistant prostate cancer has progressed after prior hormonal therapy.
-
GI-102 plus GIB-7 to target immune aging and gut‑brain‑muscle health
This trial tests whether combining GI-102 and the synbiotic GIB-7 can improve aging-related biomarkers in healthy adults and cancer survivors.
-
GI-108 monotherapy for people with advanced or metastatic solid tumors
We are testing GI-108 by itself to see if it is safe and can shrink tumors in people with advanced or metastatic solid tumors, including lung, head and neck, and pancreatic cancers.
-
Evaluating GI-102 for advanced solid tumors with or without other cancer drugs
This study is testing a new cancer treatment called GI-102, both on its own and with other cancer drugs, to see how safe it is and how well it works for people with advanced solid tumors.
-
Evaluating GI-101 with Pembrolizumab, Lenvatinib, or Radiotherapy in Advanced Solid Tumors
This study is testing a new treatment called GI-101, alone and with other therapies, to see if it can help people with advanced solid tumors.
Quick answers
How many clinical trials run by GI Innovation, Inc. are recruiting right now?
5, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 3 countries. The most sites are in South Korea (4 trials), United States (3 trials), Australia (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1/2: 4, Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.